Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Breast 2Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 75HER2-positive Breast Cancer 10Neoplasms 8Neoplasm Metastasis 4Colonic Neoplasms 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Prostatic Neoplasms 3Multiple Myeloma 3Hematologic Neoplasms 3Endometrial Neoplasms 3Brain Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Urinary Bladder Neoplasms 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Pathologic Complete Response 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Inflammatory Breast Neoplasms 2HER2-positive Early Breast Cancer 2Colorectal Neoplasms 2Breast Diseases 2Biliary Tract Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1

Interventions

pembrolizumab 105Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 47Nivolumab 40Paclitaxel 35Gemcitabine 30Radiosurgery 29Carboplatin 28Irinotecan 22Ipilimumab 22Cyclophosphamide 22Cisplatin 22trastuzumab deruxtecan 21Leucovorin 19Capecitabine 19Fluorouracil 18Cetuximab 18Bevacizumab 18130-nm albumin-bound paclitaxel 18Pemetrexed 17Fulvestrant 17Drug Therapy 16Docetaxel 16Taxes 15Oxaliplatin 15olaparib 14abemaciclib 14Radiotherapy 14palbociclib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasm Metastasis × pertuzumab × 1 year × Clear all
NCT04784715 2026-05-22

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

AstraZeneca

Phase 3 Active not recruiting
1,157 enrolled 1 FDA
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT04802759 2026-05-11

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Hoffmann-La Roche

Phase 1/2 Recruiting
316 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05150691 2026-01-28

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

DualityBio Inc.

Phase 1/2 Recruiting
796 enrolled
BreastGastrointestinalGynecologicThoracic

Bile Duct Neoplasms, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT00781612 2025-12-24

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Genentech, Inc.

Phase 2 Active not recruiting
720 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡